ADMA Biologics (NASDAQ:ADMA) Stock Price Down 10.8% – Here’s What Happened

ADMA Biologics, Inc. (NASDAQ:ADMA) was down 10.8% during mid-day trading on Monday . The company traded as low as $18.94 and last traded at $19.00. Approximately 3,666,268 shares were traded during mid-day trading, an increase of 25% from the average daily volume of 2,936,019 shares. The stock had previously closed at $21.31.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Stock Performance

The firm has a fifty day moving average of $18.26 and a 200 day moving average of $18.21. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The stock has a market capitalization of $4.64 billion, a price-to-earnings ratio of 70.14 and a beta of 0.53.

Hedge Funds Weigh In On ADMA Biologics

Several large investors have recently made changes to their positions in the company. GAMMA Investing LLC raised its position in shares of ADMA Biologics by 106.6% in the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 967 shares during the period. Mark Sheptoff Financial Planning LLC acquired a new stake in ADMA Biologics in the fourth quarter valued at approximately $35,000. Vision Financial Markets LLC acquired a new position in shares of ADMA Biologics during the 4th quarter worth approximately $51,000. Farther Finance Advisors LLC lifted its position in shares of ADMA Biologics by 1,149.1% during the 1st quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 2,505 shares in the last quarter. Finally, AlphaQuest LLC acquired a new stake in ADMA Biologics in the 4th quarter valued at $84,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.